Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 June 2021 | Story Leonie Bolleurs | Photo Supplied
The Department of Engineering Sciences (EnSci) – under the leadership of Dr Abdolhossein Naghizadeh – is heading a collaboration of scientists to create a green concrete that will reduce the impact of cement on the environment.

Conventional cement production is responsible for more than 6% of the overall carbon emissions in the world, which ultimately affects global warming.

The Department of Engineering Sciences (EnSci) at the University of the Free State (UFS) – under the leadership of Dr Abdolhossein Naghizadeh – is heading a collaboration of scientists from universities in South Africa and abroad to create a green concrete that will reduce the impact of cement on the environment.

This product has the potential to be used as an alternative to conventional concrete in large-scale constructions such as residential buildings and infrastructure, as well as small-scale constructions such a pavements and brickworks. 

Dr Nagizadeh, whose passion is cement and green concrete, says the idea of eco-friendly concrete was considered by European researchers a few years ago; however, this technology is still in its initial stages and has not been researched and employed at industrial scale yet. He believes that it is due to the complexity of the preparation process, and the relatively aggressive chemicals used in green concrete mixtures.

Expertise and equipment 

With his knowledge and experience of the product, Dr Naghizadeh – who joined EnSci in 2020 – has been appointed project leader of a collaborative group of scientists from the Universities of Johannesburg, KwaZulu-Natal, Yaoundé in Cameroon, and the Erzurum Technical University in Turkey.  

“Since there are only a limited number of researchers in this field, EnSci is benefiting from the expertise of this international collaboration. The proficiency of this group of scientists are keeping the project current, based on the latest findings in the research area,” says Louis Lagrange, Head of the Department of Engineering Sciences. 

Based on this new capacity, the department decided to establish and equip a new laboratory facility dedicated to cement and concrete research, with a specific current focus on green concrete. 

In this laboratory, they want to create formulations of green concrete, based on user-friendly materials. Furthermore, they aim to simplify the preparation and mixing process. “This can introduce a more eco-friendly, desirable product that can easily be employed extensively in the construction industry,” says Lagrange.

Benefits and other advantages

Besides its ability to reduce the impact on the environment through reduced carbon emissions, the product is also described to perform at equal or even superior strength and durability compared to conventional concrete, with potentially substantial environmental and economic benefits. 

This product is also primarily made from waste materials or industrial by-products. Dr Naghizadeh explains it as follows: “Normal concrete consists of conventional (Portland) cement, sand, stone and water, while in green concrete the conventional cement part of the concrete mix is replaced by industrial wastes or by-products and alkali solutions. These alternative materials are mostly aluminosilicate materials such as fly ash (residue from coal burning process in power plants) and slag (waste material from iron extraction processes).”

“Using these waste substances as binding material in green concrete can, apart from the environmental benefits, also reduce waste and contribute to the circular economy. Annually, more than 36 million tons of fly ash are produced in South Africa alone, of which more than 90% is deposited at landfill sites. Reuse of these waste materials will moderate the related waste deposition issues, such as air and groundwater pollution.”

Production of green concrete

Currently, green concrete is mostly produced in two parts: a solid raw material and an alkali activation solution. With their project, the research group wants to develop green concrete in a powdered form, to be mixed with water, instead of a chemical. Dr Nagizadeh estimates that the construction industry will be able to benefit from their work in about two years’ time when they will have a user-friendly green concrete product ready. 

Apart from putting an eco-friendlier concrete on the market, this project is also establishing a brand-new research niche in the UFS Department of Engineering Sciences. According to Lagrange, this research has the ability to attract postgraduate students and other researchers. He is also looking forward to the international academic recognition that EnSci will receive through published articles in leading international journals, and the participation of researchers in accredited conferences arising from this project. 

Lagrange is pleased that the project is establishing EnSci as a research player of note in the engineering field, specifically in the green engineering field. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept